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In human skeletal muscle, myoblasts represent the main population of myogenic progenitors. We previously showed that,
beside their myogenic diﬀerentiation capacities, myoblasts also diﬀerentiate towards osteogenic and chondrogenic lineages,
some properties generally considered being hallmarks of mesenchymal stem cells (MSCs). MSCs are also characterized by their
immunosuppressive potential, through cell-cell contacts and soluble factors, including prostaglandin E-2 (PGE-2), transforming
growth factor-β1( T G F - β1), interleukine-10, or indoleamine 2,3-dioxygenase. We and others also reported that Galectin-1 (Gal-
1) and Semaphorin-3A (Sema-3A) were involved in MSCs-mediated immunosuppression. Here, we show that human myoblasts
induce a signiﬁcant and dose-dependant proliferation inhibition, independently of PGE-2 and TGF-β1. Our experiments revealed
that myoblasts, in culture or in situ in human muscles, expressed and secreted Gal-1 and Sema-3A. Furthermore, myoblasts
immunosuppressive functions were reverted by using blocking antibodies against Gal-1 or Sema-3A. Together, these results
demonstrate an unsuspected immunosuppressive eﬀect of myoblasts that may open new therapeutic perspectives.
1.Introduction
Human satellite cells, positioned under the basal lamina,
have been identiﬁed to be the main myogenic progenitor un-
dergoing activation, expansion into myoblasts, and self-re-
newal [1, 2]. The surface cell antigen CD56 has been consid-
ered as a speciﬁc marker for cells derived from muscle satel-
lite cells [3]. We recently showed that CD56+ myoblasts are
able to diﬀerentiate into myotubes but also into osteoblasts
and chondroblasts [4]. The ability to diﬀerentiate towards
osteogenic and chondrogenic lineages is considered to be a
functional characteristic of mesenchymal stem cells (MSCs)
[5]. Beside these diﬀerentiation potentials, MSCs have been
shown to exert an immunosuppressive role on T and B
lymphocytes, natural killer and dendritic cells [6–11]. While
themechanismsthatgovernthisimmunosuppressiveactivity
are still a matter of debate, several studies have reported the
role of cell-cell contact and soluble factors [12]. Recently,
we and others showed that MSCs exert suppressive eﬀect on
T cell through two soluble factors, Galectin-1 (Gal-1) and
Semaphorin-3A (Sema-3A) [13–15]. Gal-1 and Sema-3A are
two ligands able to bind to Neuropilin-1 (NP-1), a neuronal2 Stem Cells International
receptor constitutively expressed on T-cell surface and in-
volvedintheregulationofT-cellproliferation[16].Inmuscle
environment, Gal-1 promotes myoblast fusion and axonal
growth after muscle injury. Sema-3A is expressed by satellite
cells in injured muscle in response to hepatocyte growth
factor secretion and is involved in the control of myoﬁber in-
nervation [17, 18]. In this context, we aimed to investigate
the potential immunosuppressive function of myoblasts and
to determine the mechanisms by which they exerted this
function. We showed that human myoblasts, similarly to
MSCs, have immunosuppressive properties on PBMCs. Both
Gal-1 and Sema-3A were expressed and secreted by myo-
blasts. These secreted proteins have largely been identiﬁed as
immunosuppressive factors controlling T-cell proliferation.
OurdatarevealedthatinhibitionofPBMCsproliferationwas
driven by Gal-1 and Sema-3A, thus demonstrating that these
two soluble factors mediate the myoblasts immunosuppres-
sive eﬀect.
2.MaterialandMethods
2.1. Cell Culture. Muscle biopsies were obtained via the
Tissue Bank for Research of the French Association against
Myopathies, upon informed consent. Biopsies were 0.3–4g
res nullus specimen from orthopaedic surgery. The three
donors were adults and had no clinical signs of muscular dis-
ease.Musclebiopsieswereenzymaticallydissociatedandcells
cultured in proliferation medium promoting the expansion
ofCD56+myogeniccells,aspreviouslydescribed[19].MSCs
were isolated from washed ﬁlters used during bone marrow
(BM) graft processing for allogenic BM transplantation (n =
3). MSCs were obtained, phenotyped, and cultured as pre-
viously described [20]. Myoblasts and MSCs were used at
p a s s a g e2o r3 .
2.2. Cell Characterization. Myoblasts were stained with the
following FITC or PE-conjugated antibodies: anti-Gal-1,
-Sema-3A, -CD56, -desmin, -CD44, -CD45, -CD80, -CD86,
-CD105, -HLA Class I, -HLA Class II, or with appropriate
controls and analyzed using a FACScalibur (Becton Dickin-
son, Le Pont de Claix, France). Immunoprecipitation were
performed using Sema-3A- and Gal-1-speciﬁc antibodies
detectedbyHRP-conjugatedantibodyandrevealedwithECL
kit (Thermo Fisher Scientiﬁc, Brebi` eres, France).
Myoblastsdiﬀerentiationintomyotubeswasevaluatedby
immunoﬂuorescence staining with myosin heavy chain anti-
body (Ozyme, Saint Quentin en Yvelines, France).
2.3. Mixed Leucocyte Reaction. Peripheral blood mononu-
clearcells(PBMCs)wereisolatedfromresnullusofapheresis
product after Ficoll gradient separation. PBMCs from a
normal donor were mixed with irradiated CD56+ cells
(25Gy) and PBMCs from another healthy individual as pre-
viously described at concentrations ranging from 0.1 to
20% of PBMCs/wells (i.e., 100 to 20,000 CD56+ cells) [20].
PBMCs from a total of 8 healthy donors were used in
these experiments. After 5 days of incubation, 1μCo f3H-
thymidine (Amersham, Les Ulis, France) was added over-
night and thymidine incorporation was measured using a
β-scintillation counter (Beckman, Gagny, France) and ex-
pressed as counts per minute (cpm). The percentage of
inhibitionwascalculatedasfollows:100-(cpmMLR+MSCs/
cpm MLR) ∗ 100.
For blocking experiment, CD56+ cells were seeded at
the concentration of 20% of responder PBMCs and were in-
cubated with neutralizing Gal-1 and Sema-3A antibodies (10
to 40μg/mL, generous gift from Dr. A. Shirvan and Dr. A.
Barzilai).
2.4. Soluble Factors Production. TGF-β1 levels in myoblasts
culture supernatants were assessed by enzyme-linked im-
munosorbent assay (ELISA) using commercially available
kits (R&D Systems, Lille, France) according to manufac-
turer’s instructions. Quantitative analysis of PGE2 was per-
formed using a competitive binding technique according to
the manufacturer’s protocol (R&D systems).
2.5. RT-PCR. CD56+ cell RNA was extracted with
NucleoSpinRNA II (Macherey-Nagel, Hoerd, France). One
μg of each RNA sample was reverse-transcripted into cDNA
using iScript cDNA Synthesis Kit (Bio-Rad, USA). Speciﬁc
primers used were Gal-1, 5 -GGT-CGC-CAG-CAA-CCT-
GAA-TC-3 ,a n d5  -ATG-TAG-TTG-ATG-GCC-TCC-AG-
3 ;S e m a - 3 A ,5  -AGA-CGC-ACA-AGA-CGA-CAA-GA-3 
and 5 -GCC-TTG-ATC-TGT-CCT-GAT-GAT-3 ;R P L O( r i -
bosomal protein L15), 5 -CAT-TGC-CCC-ATG-TGA-AGT-
C-3  and 5 -GCT-CCC-ACT-TTG-TCT-CCA-GT-3 .P C R
products were analyzed by using Gel Doc 2000 System
(Bio-Rad, USA).
2.6. Immunoﬂuorescence. Muscle samples were ﬁxed in 4%
paraformaldehyde, quenched with 0.1M glycine, incubated
in permeabilizing buﬀer containing 0.1% triton and anti-
Gal-1 or anti-Sema-3A antibodies and revealed using
alexa488- or alexa547-secondary antibodies (Invitrogen,
Saint-Aubin, France).Nucleus was stained using Dapi (Invit-
rogen). Mounted slides were scanned with a Nikon Epiﬂuo
TE-2000Emicroscope(NikonInstrumentsEurope)andwere
subsequently analyzed with Image J software.
2.7. Statistical Analysis. The results were analyzed by inde-
pendent sample two-tailed and unpaired Student’s t-test and
were presented as means ± standard error deviation.
3. Results and Discussion
Phenotypically, myoblasts were shown to express CD56,
Desmin, CD44, CD105, and HLA class I, while they were
negative for the expression of CD45, HLA class II, CD80,
and CD86 (Figure 1(a)). On a functional point of view, as
expected, myoblasts were shown to diﬀerentiate into myo-
tubes (Figure 1(b)). In the present study, we demonstrated
for the ﬁrst time that human myoblasts have immunosup-
pressive functions on PBMCs in vitro. Similarly to MSCs
isolated from BM, synovium or adipose tissues, myoblasts
wereabletoinhibitPBMCsproliferationinamixed-lympho-
cyte reaction [7, 21, 22]. This inhibition was dose dependent,
with PBMCs proliferation inhibition being more eﬃcient at
higher myoblasts:PBMCs ratio (Figure 1(c)).Stem Cells International 3
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Figure 1:HumanmyoblastscharacterizationandPBMCsproliferationinhibition.(a)Immunophenotypingbyﬂowcytometryanalysis:cells
were labeled with speciﬁc antibodies (red line) or isotype control (green line). (b) Myogenic diﬀerentiation ability of CD56+ cells. Myotubes
expressed myosin heavy chain (red), nuclei were labeled with DAPI (blue). (c) PBMCs were cultured in the presence of increasing number
of myoblasts at ratio ranging from 1/1000 to 1/5. Data are means ± SEM of triplicates from one representative of at least 10 independent
experiments. P values from Student’s t-test are indicated (∗∗P <0.01, ∗∗∗P <0.001).
While the mechanisms by which MSCs exerted their im-
munosuppressiveeﬀectshavenotbeencompletelyelucidated
to date, several soluble factors have been described as key
regulators of this process. TGF-β1a n dP G E - 2h a v eb e e n
precociously reported to participate in the MSCs-mediated
regulationofimmuneresponses[7,23].ComparedtoMSCs,
myoblasts immunosuppressive properties were shown to be
independent of PGE-2 and TGF-β1. Myoblasts, alone or in
the presence of PBMCs, do not secrete PGE-2 (Figure 2(a),
left panel). Contrarily, myoblasts were found to secrete high
basal levels of TGF-β1. Furthermore, TGF-β1s e c r e t i o nw a s
signiﬁcantly increased when MSCs or myoblasts were cul-
tured in the presence of PBMCs, (Figure 2(a), right panel).
However, no signiﬁcant reversion of myoblasts immunosup-
pressive eﬀect was observed on PBMCs proliferation in the
presence of TGF-β1 blocking antibodies (Figure 2(b)).
Gal-1 and Sema-3A are two soluble factors with immu-
nosuppressive function acting through NP-1 expressed on
T cells [24, 25]. Our recent work showed that both Gal-
1 and Sema-3A were highly expressed by MSCs, conferring4 Stem Cells International
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Figure 2: Human myoblasts inhibit PBMCs proliferation independently of PGE-2 and TGFβ-1. (a) PGE-2 (left panel) and TGF-β (right
panel) levels were assessed by ELISA on culture supernatants of MSCs and myoblasts, in the presence (black bars) or absence (white bars) of
PBMCs. (b) TGF-β1 blocking antibodies (10 to 40 μg/mL) were used to neutralize the immunosuppressive activity of myoblasts on PBMCs.
PBMCs and myoblasts were cultured at a ratio 1/5.
to these cells a suppressive activity on PBMCs proliferation
[13]. We demonstrated that myoblasts expressed both these
molecules at the mRNA (Figure 3(a))a n dp r o t e i nl e v e l
(Figure 3(b)). Gal-1 and Sema-3A were also secreted, as
shown by immunoprecipitation of the myoblasts culture su-
pernatant (Figure 3(c)).
Interestingly, myoblasts secreted higher amount of Gal-
1 than of Sema-3A, contrarily to that was observed for
MSCs, used as a control. We next assessed whether Gal-1
and Sema-3A were directly involved in myoblasts-mediated
PBMCs immunosuppression, since both ligands are capable
tospeciﬁcallyinhibitPBMCsproliferation.Tothisaim,myo-
blasts and PBMCs were cocultured in the presence of neutra-
lizing Gal-1 and Sema-3A antibodies. The blockade of Gal-1
and Sema-3A, secreted by myoblasts, restored the prolifera-
tion of PBMCs in a dose-dependent manner (Figure 3(d)).
Consistently with the amounts of both molecules secreted
by myoblasts, the restoration of PBMCs proliferation was
higher with anti-Gal-1 antibodies than with anti-Sema-3A
antibodies (98% and 68% at 40μg/mL, resp.). Taken to-
gether, these results demonstrated the implication of Gal-1
and,atalesserextentofSema-3A,intheimmunosuppressiveStem Cells International 5
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Figure 3: Human myoblasts immunosuppression is mediated by Gal-1 and Sema-3A. (a, b, c) RT-PCR, ﬂow cytometric, and im-
munoprecipitation analysis of Gal-1 and Sema-3A expression and secretion by myoblasts. MSCs were used as control. Data are means ±
SEM of triplicates from one representative of at least 10 independent experiments. P values from Student’s t-test are indicated (∗∗P <
0.01, ∗∗∗P < 0.001). (d) Neutralization of Gal-1 and Sema-3A restores PBMCs proliferation. PBMCs from eight independent donors were
cultured alone (A+B) or with myoblasts (ratio 1/5) in the presence of increasing concentration of anti-Gal-1 or anti-Sema-3A antibodies (0
to 40 μg/mL). Data are means ± SD of triplicates from one representative of at least 10 independent experiments. P values from Student’s
t-test are indicated (∗P <0.05, ∗∗P <0.01, and ∗∗∗P <0.001).
properties of myoblasts. In order to evaluate the relevance
of these ﬁndings in situ, Gal-1 and Sema-3A expressions
were assessed on human muscle biopsies. Similarly to that
was observed on cultured myoblasts, both molecules were
expressed in healthy human muscles (Figures 4(a), 4(b)).
Gal-1 expression was greater than that of Sema-3A, consis-
tently with the in vitro observations.
Emerging ﬁndings have pointed out the active interac-
tions between muscle cells and the immune system. Muscle
cellssecretecytokinesinvolvedinimmuneandinﬂammatory
reactions, respond to inﬂammatory molecules, and may
act as antigen-presenting cell in particular conditions [26].
Moreover, it has been shown that, in inﬂammatory myo-
pathies, muscle cells expressed costimulatory molecules, cell
adhesion molecules, and cytokine receptors [27–29]. Our
study is limited due to the lack of experiment on myoblasts
from pathological conditions. Acknowledging these limi-
tations, our data indicate that the Sema-3A- and Gal-1-
mediated immunomodulation may contribute to protect
muscle from inﬂammatory and/or immune injuries.6 Stem Cells International
DAPI
Galectin
100 μm
(a)
DAPI
Sema-3A
100 μm
(b)
Figure 4: In situ Gal-1 and Sema-3A expression. (a) Microscopy
analysis of Gal-1 (green) expressions in situ in normal human
muscle. Bar represents 100 μm. (b) Microscopy analysis of Sema-3A
(red) expressions in situ in normal human muscle. Bar represents
100 μm. Nuclei were stained with Dapi and appeared in blue.
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